SCHEMBL5527058

SCHEMBL5527058

Cc1cccc(C(C)C)c1NC(=S)N(C)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.55
▸ NPC1 O15118 2/20 0.50
▸ ABCC1 P33527 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALOX12 P18054 1/20 0.45
▸ RAB9A P51151 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5530274 0.85 ATM (0.54) POLBNPC1ABCC1LMNAKMT2A
SCHEMBL5528059 0.84 POLB (0.49) POLBNPC1ABCC1MAPTLMNA
SCHEMBL5538579 0.80 POLB (0.55) POLBNPC1ABCC1MAPTLMNA
SCHEMBL27285024 0.73 MEN1 (0.52) LMNAALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL30013805 0.73 MAPK1 (0.54) POLBMAPTLMNAALDH1A1KMT2A
SCHEMBL25216986 0.72 LMNA (0.54) POLBMAPTLMNAALDH1A1KMT2A
SCHEMBL26605784 0.72 ATM (0.64) POLBNPC1ABCC1KMT2AALOX12
SCHEMBL5463743 0.71 MAPT (0.77) POLBNPC1ABCC1MAPTLMNA
SCHEMBL4036816 0.70 MAPK1 (0.51) MAPTLMNAALDH1A1KMT2AALOX12
SCHEMBL25193912 0.69 LMNA (0.54) POLBMAPTLMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 POLB 4518/4885NPC1 412/4885ABCC1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback